FDA to review Acusphere's Imagify

AuntMinnie.com staff writers
Jun 30, 2008

Ultrasound contrast developer Acusphere said that the U.S. Food and Drug Administration (FDA) has accepted its Imagify new drug application (NDA) for review.

Imagify is an ultrasound contrast agent designed to assess myocardial perfusion, according to the Watertown, MA-based firm.

Related Reading

Acusphere revenues flat for Q1 2008, May 9, 2008

Acusphere submits NDA for Imagify, April 29, 2008

Acusphere cuts annual net loss, March 17, 2008

Acusphere gets Nasdaq warning letter, January 14, 2008

Acusphere reports Q3 results, November 9, 2007

Copyright © 2008 AuntMinnie.com

Latest in Ultrasound
Emergency 400
Ultrasound-guided nerve blocks safe for emergency pain management
November 13, 2024
Thyroid Cancer
Thermal ablation effective long term in patients with thyroid cancer
November 7, 2024
Baby Bottle
Could cranial ultrasound sub for brain MRI in imaging infants?
November 6, 2024
Images depict a 43-year-old woman with a malignant nonmass lesion that was diagnosed as microinvasive ductal carcinoma. (A) Transverse and (B) longitudinal ultrasound images show a hypoechoic nonmass lesion (solid arrows) with segmental distribution in the left breast. The lesion has associated calcifications (dashed arrows in A). (C) Longitudinal color Doppler ultrasound image shows high vascularity. (D) Magnified image in the mediolateral oblique view from screening mammography shows grouped calcifications (arrows), which are considered a mammographic correlate of the ultrasound-detected nonmass lesion (A radiopaque marker attached to the skin is visible in the image because the mammographic exam was performed after screening breast ultrasound). Ultrasound-guided core needle biopsy and pathologic examination revealed ductal carcinoma in situ, but the lesion was upgraded to microinvasive ductal carcinoma at subsequent surgery (2.5-cm ductal carcinoma in situ, histologic grade II, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor type 2-negative).
Ultrasound nonmass breast lesion features may signal malignancy
November 5, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2008 06 10 13 44 22 20 Rectus Femoris Thumb 2008 06 16
Ultrasound
Case study: Complete rectus femoris tear in an adolescent soccer player
2008 06 09 09 43 38 404 Vasiliev thumb 06 08
Ultrasound
Video game technology speeds beating-heart surgery
2008 03 16 22 13 45 706
Ultrasound
Pictorial essay: 3D ultrasound reveals shoulder pathology
More in Ultrasound
Ultrasound-guided nerve blocks safe for emergency pain management
By Amerigo Allegretto
Ultrasound-guided nerve blocks (UGNBs) performed by emergency clinicians could be safe for pain management.
November 13, 2024
Emergency 400
Thermal ablation effective long term in patients with thyroid cancer
By Will Morton
Outcomes over 10 years suggest that image-guided thermal ablation is a safe and effective option for patients with papillary thyroid carcinoma.
November 7, 2024
Thyroid Cancer
Could cranial ultrasound sub for brain MRI in imaging infants?
By Amerigo Allegretto
Cranial ultrasound could have utility for imaging infants with hypoxic-ischemic encephalopathy.
November 6, 2024
Baby Bottle
Ultrasound nonmass breast lesion features may signal malignancy
By Amerigo Allegretto
Some nonmass breast lesion characteristics on ultrasound exams can be considered suspicious for malignancy at screening ultrasound.
November 5, 2024
Images depict a 43-year-old woman with a malignant nonmass lesion that was diagnosed as microinvasive ductal carcinoma. (A) Transverse and (B) longitudinal ultrasound images show a hypoechoic nonmass lesion (solid arrows) with segmental distribution in the left breast. The lesion has associated calcifications (dashed arrows in A). (C) Longitudinal color Doppler ultrasound image shows high vascularity. (D) Magnified image in the mediolateral oblique view from screening mammography shows grouped calcifications (arrows), which are considered a mammographic correlate of the ultrasound-detected nonmass lesion (A radiopaque marker attached to the skin is visible in the image because the mammographic exam was performed after screening breast ultrasound). Ultrasound-guided core needle biopsy and pathologic examination revealed ductal carcinoma in situ, but the lesion was upgraded to microinvasive ductal carcinoma at subsequent surgery (2.5-cm ductal carcinoma in situ, histologic grade II, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor type 2-negative).
ChatGPT demonstrates mixed results in assigning BI-RADS categories
By Amerigo Allegretto
ChatGPT achieves modest accuracy when assigning BI-RADS scores for mammograms and breast ultrasound exams.
November 1, 2024
Chat Gpt 400
ABUS screening improves breast cancer screening in low-resource areas
By Amerigo Allegretto
Automated breast ultrasound (ABUS) with remote reading may improve access to breast cancer screening and early detection in low-resource settings.
October 29, 2024
Ultrasound Breast 400
Ukraine's top pediatric hospital rebuilds after bomb attack
By Philip Ward
Radiology staff at the Ohmatdyt Children's Hospital in Kyiv are making steady progress with their plan to restore normal service after a devastating missile attack.
October 25, 2024
Thanks to the support of the global imaging community, radiology staff at the Ohmatdyt can now look forward to restoring normal service.
CNN models using ultrasound images detect pancreatic neoplasms
By Amerigo Allegretto
A deep-learning method using endoscopic ultrasound images could detect pancreatic neuroendocrine neoplasms.
October 18, 2024
Ultrasound Scanner Computerized 400
Ultrasound method detects cellular rejection in liver transplant cases
By Amerigo Allegretto
An ultrasound measurement technique could detect and stage acute cellular rejection in liver transplant patients.
October 16, 2024
Ultrasound Diagnostic Control Panel
Could elastography replace conventional ultrasound-guided FNAC?
By Amerigo Allegretto
Strain elastography does not have additional benefits over conventional elastography-guided FNAC for diagnosing malignancy in thyroid nodules.
October 15, 2024
Images depict a 43-year-old woman with a solitary left-sided thyroid nodule classified at gray-scale ultrasound as category U3, upgraded to category U4 at strain elastography, and classified as category Thy4 at cytopathologic examination. Subsequent surgical histopathologic examination confirmed papillary cell carcinoma. (A) Longitudinal view of the left thyroid lobe demonstrates the low reflective nodule (between arrows) measuring 13 × 12 × 11 mm (not shown) and with a halo. (B) A longitudinal image with side-by-side visualization of the nodule (arrow) at gray scale (left) and strain elastography (right). The nodule is predominantly blue, indicating increased stiffness. (C) A longitudinal view shows the needle (arrows) within the stiffer aspect of the nodule for cytology sampling. U and Thy categories are according to British Thyroid Association system. Image courtesy of the RSNA.
Ultrasound test detects 96% of ovarian cancers
By Kate Madden Yee
An ultrasound test can identify 96% of ovarian cancers in postmenopausal women, researchers have reported.
October 1, 2024
Ovarian Cancer
Publicly insured pregnant women less likely to get 20-week ultrasounds
By Amerigo Allegretto
Twenty-week ultrasound exams for pregnant women drives disparities in prenatal diagnosis of congenital heart defects.
September 23, 2024
Fetal Ultrasound
Page 1 of 512
Next Page